SOURCE: Linkage Biosciences

Linkage Biosciences

November 07, 2014 08:00 ET

Linkage Biosciences Adds to Board Leadership

SAN FRANCISCO, CA--(Marketwired - Nov 7, 2014) - Linkage Biosciences, a leading manufacturer of tissue transplantation diagnostic products, announced the election of Mr. Lewis J. Stuart to the company's Board of Directors. The election reflects Linkage's continued focus on expansion in both domestic and international markets.

Mr. Stuart has more than 30 years of global healthcare commercial experience across multiple sectors including oncology, cardiovascular, and infectious disease. Currently, Mr. Stuart is Vice-President of Sales and Marketing at Genomic Health, Inc., a leader and pioneer in molecular oncology diagnostics. Prior to Genomic Health, Mr. Stuart served as President and General Manager of Phenogen Sciences, a North American subsidiary of Australia-based, Genetic Technologies, Inc. Mr. Stuart spent over eight years in several commercial roles at CV Therapeutics, now a division of Gilead Sciences, and has held senior leadership positions at both Pfizer and Bristol Myers Squibb, notably leading the launch of Viracept, a lifesaving treatment for HIV/AIDS.

"Lewis brings an extensive commercial leadership background to the Board at an important time in our development," said Zachary Antovich, CEO of Linkage Biosciences. "We look forward to benefiting from Lewis' insights as we execute our growth initiatives."

About Linkages Biosciences
Linkage Biosciences, Inc. is a molecular diagnostics company developing and marketing products that dramatically improve and expedite complex genetic testing. LinkSēq™, the company's HLA testing product line, is used in immunogenetics research and histocompatibility testing. The company is headquartered in South San Francisco, California. To learn more please visit

Copyright 2014. Linkage Biosciences, Inc. All rights reserved.
Linkage Biosciences and LinkSēq are trademarks of Linkage Biosciences, Inc.